Seale John Paul
University of Sydney, Broadway, Sydney, NSW 2006, Australia.
IDrugs. 2010 Nov;13(11):762-4.
The European Respiratory Society Congress, held in Barcelona, included topics covering new therapeutic developments in the field of respiratory health and disease. This conference report highlights selected presentations on therapies targeting inflammatory cells, with a focus on therapeutic agents for asthma and COPD. This report also includes a discussion of novel therapeutic agents for pulmonary hypertension. Investigational drugs discussed include OC-000459 (Oxagen), SCH-527123 (Merck & Co), AZD-9668 (AstraZeneca), benralizumab (MedImmune/Kyowa Hakko Kirin/BioWa), PF-3429281 (Pfizer), vilanterol (GlaxoSmithKline/Theravance), LAS-100977 (Almirall Prodesfarma), selexipag (Nippon Shinyaku/Actelion) and GW-0742 (GlaxoSmithKline).
在巴塞罗那举行的欧洲呼吸学会大会涵盖了呼吸健康与疾病领域新治疗进展的诸多主题。本会议报告重点介绍了有关针对炎症细胞疗法的精选演讲,尤其关注哮喘和慢性阻塞性肺疾病(COPD)的治疗药物。本报告还讨论了用于肺动脉高压的新型治疗药物。所讨论的研究性药物包括OC - 000459(奥克森公司)、SCH - 527123(默克公司)、AZD - 9668(阿斯利康公司)、贝那利珠单抗(麦迪免疫/日本协和发酵麒麟/保和制药)、PF - 3429281(辉瑞公司)、维兰特罗(葛兰素史克/瑟法隆公司)、LAS - 100977(艾尔米兰制药)、司来帕格(日本新药/爱可泰隆公司)以及GW - 0742(葛兰素史克公司)。